Objective: Investigate the neuroprotective effect of a novel compound in an animal model of Parkinson’s disease.
Background: Cerebral dopamine neurotrophic factor (CDNF) and mesencephalic astrocyte-derived neurotrophic factor (MANF) have shown neuroprotective and neurorestorative effects in animal models of Parkinson’s disease. Novel neurotrophic compounds have been developed based on the structure of CDNF and MANF, and these compounds’ effects will be investigated in the 6-hydroxydopamine (6-OHDA) rat model.
Method: 6-hydroxydopamine (6-OHDA) was unilaterally injected to rat striatum to generate partial lesion of nigrostriatal dopamine pathway. Amphetamine-induced rotation test was conducted two weeks later. Successfully lesioned animals were divided into treatment groups, which received either the novel neurotrophic compound or vehicle. After sacrificing animals, dopamine neuron depletion was studied by doing immunohistochemical staining against tyrosine hydroxylase (TH). Further to that, effects of the studied compound on different cellular markers of endoplasmic reticulum stress and inflammation were investigated.
Results: The study is still ongoing. Results will be presented at the conference.
Conclusion: Final conclusions will be shown at the conference when the study has been completed.
To cite this abstract in AMA style:
T. Viljakainen, M. Voutilainen. Effects of a novel neurotrophic compound in an animal model of Parkinson’s disease [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/effects-of-a-novel-neurotrophic-compound-in-an-animal-model-of-parkinsons-disease/. Accessed May 25, 2025.« Back to 2022 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/effects-of-a-novel-neurotrophic-compound-in-an-animal-model-of-parkinsons-disease/